PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
Conference Call and Webcast at 8:30 AM Eastern Time
美国东部时间上午 8:30 的电话会议和网络直播
NEW YORK, July 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, August 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's second quarter 2024 financial results.
纽约，2024年7月30日 /PRNewswire/ — PAVMed Inc.（纳斯达克股票代码：pavM，PAVMZ）（“PAVMed” 或 “公司”）是一家在医疗器械、诊断和数字健康领域运营的多元化商业阶段医疗技术公司，今天宣布，它将在美国东部时间2024年8月13日星期二上午8点30分举办业务最新电话会议和网络直播。在电话会议上，PavMed董事长兼首席执行官Lishan Aklogwand.D. 将提供最新业务情况，包括公司的运营和增长战略概述。此外，PavMed总裁兼首席财务官丹尼斯·麦格拉思将讨论公司2024年第二季度的财务业绩。
The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.
该网络直播将在公司网站pavmed.com的投资者关系部分播出。或者，要通过电话参加电话会议，美国的来电者应拨打1-800-836-8184，国际听众应拨打1-646-357-8785。所有听众都应向运营商提供电话会议名称 “PavMed 业务更新” 以加入。
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
电话会议结束后，公司网站pavmed.com的投资者关系部分将提供为期30天的重播。
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other main subsidiary, Veris Health, is focused on commercialization of its digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiologic monitor containing biologic sensors capable of generating continuous data on key physiologic parameters known to predict adverse outcomes in cancer patients undergoing treatment.
关于 PAVMed
PavMed Inc. 是一家多元化的商业阶段医疗技术公司，业务涉及医疗器械、诊断和数字医疗领域。其子公司Lucid Diagnostics（纳斯达克股票代码：LUCD）是一家处于商业阶段的癌症预防医疗诊断公司，销售ESOGuard食管DNA测试和ESOCheck食管细胞收集设备，这是第一款也是唯一一种广泛早期发现食管癌前病以降低食道癌死亡风险的商业工具。其另一家主要子公司Veris Health专注于其数字癌症护理平台的商业化，该平台具有生理数据收集、症状报告和远程医疗功能，旨在通过远程患者监测改善个性化癌症护理。Veris还一直在开发一种包含生物传感器的植入式生理监测器，该监视器能够生成有关已知的关键生理参数的连续数据，这些参数可以预测接受治疗的癌症患者的不良后果。
For more and for more information about PAVmed, please visit pavmed.com.
如需了解有关 PavMed 的更多信息以及更多信息，请访问 pavmed.com。
For more information about Lucid Diagnostics, please visit luciddx.com.
有关 Lucid Diagnostics 的更多信息，请访问 luciddx.com。
For more information about Veris Health, please visit verishealth.com.
有关 Veris Health 的更多信息，请访问 verishealth.com。
SOURCE PAVmed Inc.
来源 PavMed Inc.